What's Happening?
SetPoint Medical is set to present new data at the ACR Convergence 2025, showcasing the sustained efficacy and safety of its SetPoint System for treating rheumatoid arthritis (RA). The system, which uses
neuroimmune modulation therapy, has demonstrated significant clinical efficacy over 12 months, inhibiting joint erosion progression. The data comes from the RESET-RA study, a pivotal trial involving 242 patients with moderate-to-severe RA who were incomplete responders or intolerant to biologic or targeted synthetic DMARDs. The study met its primary efficacy endpoint and showed a favorable safety profile, leading to FDA approval in July 2025.
Why It's Important?
The SetPoint System offers a novel, device-based alternative for RA patients who do not respond to or cannot tolerate existing biologic or JAK inhibitor therapies. This development is crucial for the medical community, as it provides a new therapeutic option that could improve patient outcomes and reduce reliance on pharmaceutical treatments. The positive reception of the system by patients underscores the demand for innovative solutions in managing chronic autoimmune diseases.
What's Next?
SetPoint Medical plans to continue evaluating its neuroimmune modulation platform for other autoimmune conditions, such as multiple sclerosis and Crohn's disease. The company will likely engage with healthcare providers and regulatory bodies to expand the system's application and ensure its integration into standard treatment protocols. The upcoming presentations at ACR Convergence 2025 will further highlight the system's potential, potentially influencing future research and development in the field.
Beyond the Headlines
The success of the SetPoint System could lead to a paradigm shift in treating autoimmune diseases, emphasizing device-based therapies over traditional pharmaceuticals. This approach may inspire further innovation in medical technology, encouraging the exploration of neuroimmune modulation for a broader range of conditions.
